Insider Buying: Xilio Therapeutics, Inc. (NASDAQ:XLO) Director Purchases $17,250.00 in Stock

Xilio Therapeutics, Inc. (NASDAQ:XLO) Director James Samuel Shannon purchased 25,000 shares of the stock in a transaction dated Tuesday, June 17th. The shares were bought at an average cost of $0.69 per share, for a total transaction of $17,250.00. Following the completion of the purchase, the director now owns 70,000 shares in the company, valued at approximately $48,300. This trade represents a 55.56% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

James Samuel Shannon also recently made the following trade(s):

• On Monday, June 16th, James Samuel Shannon purchased 45,000 shares of Xilio Therapeutics stock. The shares were bought at an average cost of $0.69 per share, for a total transaction of $31,050.00.

Xilio Therapeutics Trading Up 4.2%

Shares of NASDAQ XLO opened at $0.69 on Friday. The stock has a market cap of $35.65 million, a price-to-earnings ratio of -0.82 and a beta of -0.01. Xilio Therapeutics, Inc. has a 52 week low of $0.62 and a 52 week high of $1.70. The company’s 50-day moving average price is $0.78 and its 200 day moving average price is $0.87.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.28). The business had revenue of $2.93 million during the quarter, compared to analyst estimates of $42.00 million. Xilio Therapeutics had a negative net margin of 585.54% and a negative return on equity of 262.69%. As a group, research analysts expect that Xilio Therapeutics, Inc. will post -1.14 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Xilio Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd.

Institutional Investors Weigh In On Xilio Therapeutics

Large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in Xilio Therapeutics in the 4th quarter valued at about $48,000. Renaissance Technologies LLC lifted its holdings in Xilio Therapeutics by 11.4% in the 4th quarter. Renaissance Technologies LLC now owns 296,617 shares of the company’s stock valued at $283,000 after purchasing an additional 30,317 shares in the last quarter. Gilead Sciences Inc. purchased a new position in Xilio Therapeutics in the 4th quarter valued at about $8,696,000. Geode Capital Management LLC lifted its holdings in Xilio Therapeutics by 6.0% in the 4th quarter. Geode Capital Management LLC now owns 358,422 shares of the company’s stock valued at $342,000 after purchasing an additional 20,230 shares in the last quarter. Finally, Takeda Pharmaceutical Co. Ltd. purchased a new position in Xilio Therapeutics in the 4th quarter valued at about $1,416,000. 54.29% of the stock is owned by institutional investors and hedge funds.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.